Skip to main content
Solid radium sulfate sits in the bottom of a flask during the recovery process. Credit: Oak Ridge National Laboratory, U.S. Dept. of Energy

Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.

At the U.S. Department of Energy Manufacturing Demonstration Facility at ORNL, this part for a scaled-down prototype of a reactor was produced for industry partner Kairos Power.

Scientists at the Department of Energy Manufacturing Demonstration Facility at ORNL have their eyes on the prize: the Transformational Challenge Reactor, or TCR, a microreactor built using 3D printing and other new approaches that will be up and running by 2023.

The electromagnetic isotope separator system operates by vaporizing an element such as ruthenium into the gas phase, converting the molecules into an ion beam, and then channeling the beam through magnets to separate out the different isotopes.

A tiny vial of gray powder produced at the Department of Energy’s Oak Ridge National Laboratory is the backbone of a new experiment to study the intense magnetic fields created in nuclear collisions.

Radiochemical technicians David Denton and Karen Murphy use hot cell manipulators at Oak Ridge National Laboratory during the production of actinium-227.

The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.

By producing 50 grams of plutonium-238, Oak Ridge National Laboratory researchers have demonstrated the nation’s ability to provide a valuable energy source for deep space missions.

With the production of 50 grams of plutonium-238, researchers at the Department of Energy’s Oak Ridge National Laboratory have restored a U.S. capability dormant for nearly 30 years and set the course to provide power for NASA and other missions.